Alfa Cytology Launches RDC Linker Design and Radioligand Binding Analysis Research Support Platform
Alfa Cytology supports RDC structural design and target binding studies through linker design services and radioligand binding assay platforms. New York, United States, March 30, 2026 — With the rapid development of radio-targeted therapy, Radionuclide… Read More »Alfa Cytology Launches RDC Linker Design and Radioligand Binding Analysis Research Support Platform





